Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Ophthalmology. 2016 Feb 27;123(6):1351–1359. doi: 10.1016/j.ophtha.2016.02.022

Figure 1.

Figure 1

Figure 1

Figure 1

Mean Change in Visual Acuity over Time, A) Overall; B) and C) Stratified by baseline visual acuity (approximate Snellen equivalent): 20/50 or worse (B) and 20/32-20/40 (C). Change in visual acuity was truncated to 3 standard deviations from the mean. The number of eyes at each time point ranged from 195-224 in the aflibercept group, 185-218 in the bevacizumab group, and 188-218 in the ranibizumab group (see Figure S1 in the Supplementary Appendix and Figure S2 in the 1 Year Supplementary Appendix2 for the number at each time point).